Trial Profile
Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Cabazitaxel; Carboplatin; Prednisone
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- 01 May 2023 Planned End Date changed from 1 Apr 2023 to 30 Jun 2024.
- 01 May 2023 Planned primary completion date changed from 1 Apr 2023 to 30 Jun 2024.
- 18 Feb 2023 Results (n=96) assessing the heterogeneity of an aggressive subset of prostate cancers by linking genomic and transcriptomic analyses with clinical outcomes, presented at the 2023 Genitourinary Cancers Symposium.